Monitor for future expansion of this collaboration into a commercial supply agreement or licensing deal, which would provide a clearer revenue path. The partnership validates PacBio's technology for AI-driven drug discovery but lacks near-term financial impact.
Price Chart
Executive Summary
PacBio announced a collaboration with TychoBio, an AI drug discovery company, to generate full-length RNA data using PacBio's HiFi and Kinnex long-read sequencing technologies. TychoBio will sequence over 10,000 samples to train AI models for RNA therapy design, with plans to expand to siRNA and other compounds. This is a non-exclusive, non-financial collaboration that validates PacBio's sequencing technology for AI-driven drug discovery but does not include upfront payments or revenue commitments.
Key Facts
- TychoBio will use PacBio HiFi and Kinnex long-read RNA sequencing to generate data from more than 10,000 samples.
- Data will train AI models for designing steric blocking antisense oligonucleotides (SBOs), with plans to expand to siRNA and other RNA-targeting compounds.
- No financial terms (upfront payments, milestones, or royalties) were disclosed in the press release.
- The collaboration is framed as a research-use partnership, not a commercial supply or licensing agreement.
- PacBio CEO Mark Van Oene highlighted the collaboration as demonstrating the value of high-quality sequencing data for AI ecosystem biological modeling.
Financial Impact
No financial terms disclosed; collaboration is non-revenue-generating at this stage.
Risk Factors
- No disclosed financial terms suggest this is a low-revenue or non-revenue collaboration.
- AI drug discovery partnerships often have high failure rates and long timelines to commercialization.
- Competing sequencing technologies (e.g., Illumina, Oxford Nanopore) could also be used for similar RNA data generation.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3375612 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $1.84 $2.27 | ▲ +23.10% | ▲ +23.24% | $2.25 (+22.28%) |
Oct 6, 2026 20d ago | 144 | $2.72 $1.99 | ▲ +26.84% | ▲ +25.86% | $2.25 (+17.28%) |
Oct 6, 2026 20d ago | Press Release | $2.70 $2.05 | ▼ −24.07% | ▼ −23.94% | $2.25 (−16.67%) |
Jun 4, 2026 20w ago | 8-K | $1.45 $1.31 | ▼ −9.66% | ▼ −10.22% | $2.25 (+55.17%) |
May 22, 2026 22w ago | DEFA14A | $1.26 $1.58 | ▲ +25.40% | ▲ +24.31% | $2.25 (+78.57%) |
Apr 21, 2026 26w ago | Press Release | $1.73 $1.58 | ▼ −8.67% | ▼ −9.75% | $2.25 (+30.06%) |
Apr 16, 2026 27w ago | Press Release | $1.69 $1.56 | ▼ −7.69% | ▼ −8.25% | $2.25 (+33.14%) |
Mar 5, 2026 33w ago | 8-K | $1.52 $1.27 | ▼ −16.45% | ▼ −14.21% | $2.25 (+48.03%) |
Mar 3, 2026 33w ago | Insider Cluster | $1.52 $1.37 | ▼ −9.87% | ▼ −9.39% | $2.25 (+48.03%) |
Feb 28, 2026 34w ago | Institutional Cluster | $1.62 $1.39 | ▼ −14.20% | ▼ −12.99% | $2.25 (+38.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers